Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.75.
A number of research analysts have commented on the stock. Lake Street Capital decreased their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 24th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Cellebrite DI in a research report on Wednesday.
Check Out Our Latest Research Report on Cellebrite DI
Cellebrite DI Stock Performance
CLBT stock opened at $18.99 on Thursday. Cellebrite DI has a one year low of $13.10 and a one year high of $26.30. The firm has a market cap of $4.55 billion, a PE ratio of -24.99, a PEG ratio of 3.36 and a beta of 1.29. The firm's 50 day moving average price is $16.50 and its 200-day moving average price is $16.98.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same period in the prior year, the business posted $0.10 earnings per share. The firm's revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. acquired a new stake in Cellebrite DI in the 1st quarter valued at about $60,939,000. Invesco Ltd. raised its holdings in Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after acquiring an additional 1,811,757 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in Cellebrite DI by 749.9% in the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after acquiring an additional 1,340,000 shares during the last quarter. Voss Capital LP lifted its stake in Cellebrite DI by 34.0% in the second quarter. Voss Capital LP now owns 5,150,000 shares of the company's stock worth $82,400,000 after acquiring an additional 1,306,398 shares during the last quarter. Finally, Phoenix Financial Ltd. lifted its stake in Cellebrite DI by 153.5% in the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company's stock worth $32,232,000 after acquiring an additional 1,219,958 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.
Cellebrite DI Company Profile
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
